Bone marrow transplantation is potentially curative therapy for the hematologic complications associated with Shwachman-Diamond syndrome (SDS). This syndrome is, however, also associated with significant pancreatic and hepatic dysfunction, which may complicate BMT. We report a case of liver failure due to nonalcoholic steatohepatitis (NASH) following BMT for SDS. This case illustrates the need for assessing liver dysfunction pre-BMT in these patients, in addition to highlighting the potential risk posed by pre-existing steatosis for the development of rapidly progressive hepatic failure following transplantation. Bone Marrow Transplantation (2002) 29, 931-933. DOI: 10.1038/sj/bmt/1703549 Keywords: Shwachman-Diamond; steatohepatitis; bone marrow transplant Initially described in 1964, Shwachman-Diamond syndrome (SDS) is an autosomal recessive disorder characterized by short stature, exocrine pancreatic insufficiency, metaphyseal dysostosis, chronic respiratory disease and bone marrow dysfunction.
Initially described in 1964, Shwachman-Diamond syndrome (SDS) is an autosomal recessive disorder characterized by short stature, exocrine pancreatic insufficiency, metaphyseal dysostosis, chronic respiratory disease and bone marrow dysfunction. 1, 2 The most constant hematological abnormality is neutropenia, which is associated with recurrent bacterial infections in early childhood. 2 Pancytopenia due to myelodysplasia is recognized in 10-25% of cases, with progression to marrow failure, or myeloid leukemia in a smaller proportion. 3 The hematologic manifestations of SDS may be cured by allogeneic bone marrow transplantation (BMT). To date there have been 13 documented cases of BMT, predominantly in children with SDS (reviewed by Faber et al 4 ), of whom five are alive with a median follow-up of 24 months. Reported complications of BMT in this patient group include cardiomyopathy, 5 status epilepticus, 6 renal tubular acidosis, 6 and veno-occlusive disease. Despite the finding of sub-clinical hepatic steatosis in up to 30% of SDS patients, 2,8,9,10 steatohepatitis has not been reported previously as a complication following BMT in SDS. We describe the development of fatal liver failure complicating progressive non-alcoholic steatohepatitis (NASH) in an adult patient with SDS undergoing BMT.
Case report
A 35-year-old woman with long-standing SDS was referred for BMT. She was the only child of unrelated Caucasian parents and had presented initially at 6 months of age with recurrent bacterial infections and failure to thrive. Investigations at presentation confirmed pancreatic insufficiency and the diagnosis of SDS was made. Steatorrhoea, which had been a prominent symptom, was subsequently controlled with pancreatic enzyme supplementation. Progressive neutropenia (neutrophil count 0.2-0.7 × 10 9 /l) with associated recurrent lower respiratory tract infections developed over the 24 months prior to transplantation. Bone marrow assessment confirmed the development of myelodysplasia and duplication of chromosome 1q in 32 of 42 metaphases. In view of progressive neutropenia and the association between dup(1q) and risk of leukemic progression, allogeneic BMT was recommended from a phenotypically identical maternal uncle as a donor.
There was no clinical evidence of chronic liver disease on admission examination, and no history of alcohol abuse. She was obese, with a body mass index of 32 (normal Ͻ27). Pre-BMT liver function tests (LFT) revealed an isolated elevation of alkaline phosphatase (ALP) at 141 IU/l (reference range (RR) 0-120 IU/l). All other LFTs were unremarkable: bilirubin 5 mol/l (RR 0-19 mol/l), alanine aminotransaminase (ALT) 16 IU/l (RR 0-55 IU/l), gamma glutamyltransferase (GGT) 23 IU/l (RR Ͻ50 IU/l) albumin 37 g/l (RR 35-50 g/l). Coagulation studies were normal. Computed tomography (CT) of the liver in retrospect showed diffuse low-density change consistent with fatty infiltration ( Figure 1) ; this was not reported at the time. Cardiac, renal and respiratory function were normal. Random blood glucose was 4.8 mmol/l (RR 3.6-7.7 mmol/l). Hepatitis A, B and C serology were negative prior to BMT and again at day 100. A combined oral contraceptive, used from the age of 25 to control dysfunctional uterine bleeding, was discontinued immediately prior to BMT.
Conditioning was undertaken with cyclophosphamide (120 mg/kg over 2 days) and total body irradiation (12 Gy in six fractions). Graft-versus-host disease (GVHD) prophylaxis was with cyclosporin 3 mg/kg per day from day −1 and methotrexate 15 mg/m 2 on day 1, and 10 mg/m 2 on days 3, 6 and 11. No prophylaxis against veno-occlusive disease was used. Total parenteral nutrition (TPN) consisting of 25% dextrose and 10% lipid emulsion was started on day 7 and continued until day 32. Neutrophil recovery to Ͼ0.5 × 10 9 /l occurred on day 18 and platelet recovery to Ͼ20 × 10 9 /l on day 20. No significant disturbance of liver function occurred prior to engraftment. Bone marrow assessment at day 28 revealed tri-lineage engraftment with only donor metaphases identified.
On day 32, diffuse right upper quadrant abdominal discomfort, low-grade fever and disturbed LFTs were noted (bilirubin 54 mol/l, aspartate aminotransaminase (AST) 131 IU/l (RR 0-40 IU/l). The liver was not palpable. Abdominal ultrasound scan (USS) demonstrated abnormal echogenicity within the liver consistent with fatty change. Ascites was not present. CT of the liver suggested persistent fatty infiltration. Liver biopsy was not performed at this time. A fat-restricted diet was started with partial resolution of symptoms and discharge from hospital was achieved by day 45. Anorexia and nausea persisted post discharge, and ALP, GGT, AST and ALT remained elevated. Prednisolone 25 mg/day and ursodeoxycholic acid 750 mg/day were started for presumed hepatic GVHD. Cyclosporin was continued at 125 mg twice daily with plasma levels maintained between 250 and 300 ng/ml. Upper gastro-intestinal endoscopy and mucosal biopsy, however, revealed no evidence of GVHD, and the prednisolone dose was weaned to zero by day 75. Sternotrophomonas maltophilia bacteremia occurred on day 68, necessitating removal of the Hickman catheter, and 2 days of intravenous cefepime and a course of oral ciprofloxacin. The combined oral contraceptive pill was restarted at day 81 as hormone replacement therapy.
At day 116 increased abdominal swelling was noted and the liver edge had become palpable 9 cm below the right costal margin. Liver Doppler USS again suggested diffuse fatty infiltration, with no evidence of ascites, and normal hepatic venous flow. At day 127 acute worsening of nausea and vomiting occurred associated with increased hepatomegaly, deterioration of LFT (ALP 253 IU/l, GGT 148 IU/l, ALT 35 IU/l, AST 131 IU/l, albumin 24 g/l) and prolongation of the international normalized ratio (INR) to 2.0, which failed to correct with vitamin K 10 mg daily. Blood glucose remained normal. Serum cholesterol was 6.1 mmol/l (RR 2.6-6.9 mmol/l) and triglyceride 2.8 mmol/l (RR 0.2-2.0 mmol/l). An hepatic venogram showed no evidence of hepatic venous outflow obstruction. Liver biopsy revealed marked steatohepatitis, with Mallory bodies, early fibrosis and cholangiolitis, with no evidence of GVHD. Repeat upper endoscopy with oesophageal, gastric and duodenal biopsies showed no evidence of GVHD or viral inclusions. There was moderate dilation of capillaries in the lamina propria of the duodenum consistent with portal hypertension.
Over the subsequent 8 days there was progressive hyperbilirubinemia (bilirubin 257 mol/l) and elevation of ammonia to 181 mol/l (RR Ͼ55 mol/l). Cultures of blood and ascitic fluid were negative. Renal failure, progressive obtundation and dyspnoea requiring ventilatory support ensued and multi-organ failure led to death 135 days post BMT. Post-mortem examination confirmed marked non-alcoholic steatohepatitis with bridging fibrosis and cholangitis lenta (Figure 2) . The pancreas showed complete exocrine lobular atrophy and fatty replacement. Transudates were present within the pleural and pericardial spaces and extensive ascites was present. The lungs demonstrated diffuse alveolar damage. No organisms were identified on microscopy or culture of pulmonary tissue. There was no evidence of splenomegaly or oesophageal varices. Examination of the bone marrow revealed tri-lineage engraftment.
Discussion
The diagnosis of NASH requires exclusion of alcohol abuse and histological demonstration of steatosis in association with necro-inflammatory foci, ballooning degeneration of hepatocytes with or without Mallory bodies and pericellular fibrosis. 11 The precise pathogenesis of NASH is still debated, but it is associated with a number of conditions including obesity, insulin resistance, TPN, jejunoileal bypass, and exposure to a wide range of drugs including glucocorticoids and synthetic oestrogens. 12 More recently, small intestinal bacterial overgrowth has been recognized as a potential precipitant of NASH, via the elevation of circulating levels of tumor necrosis factor alpha. 13 A number of these risk factors are present in the majority of patients undergoing BMT; a recent report identified NASH in 2.8% of 106 allogeneic BMT recipients. 14 While most individuals with hepatic steatosis within the general population do not develop serious liver disease, a proportion develop NASH, which may lead to fibrosis, cirrhosis and liver failure. 15 In our patient, pre-existing hepatic steatosis is likely to have predisposed to the development of progressive NASH following TPN, glucocorticoid and/or oestrogen exposure post transplant.
Our experience confirms that the absence of disturbed LFTs or clinical evidence of liver dysfunction does not exclude the diagnosis of steatosis, and suggests that imaging of the liver with either US or CT should be performed as part of pre-BMT screening in patients with SDS. The outcome in this case indicates that pre-existing liver disease Bone Marrow Transplantation in such patients may increase the risks associated with BMT. The relative success of BMT for SDS in children may, in part, reflect a lower incidence of hepatic steatosis. In older patients with this condition, however, the risks associated with long-standing hepatic and pancreatic disease need to be weighed against the risk of leukemic progression.
